* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download deuterium-modified dextromethorphan and ultra
Survey
Document related concepts
Drug design wikipedia , lookup
Compounding wikipedia , lookup
Adherence (medicine) wikipedia , lookup
Prescription drug prices in the United States wikipedia , lookup
Pharmacokinetics wikipedia , lookup
Prescription costs wikipedia , lookup
Pharmaceutical industry wikipedia , lookup
Neuropharmacology wikipedia , lookup
Theralizumab wikipedia , lookup
Pharmacogenomics wikipedia , lookup
List of off-label promotion pharmaceutical settlements wikipedia , lookup
Transcript
Avanir Pharmaceuticals, Inc. is a leading specialty biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system (CNS) disorders of high unmet medical need. We are dedicated to advancing medicines that can substantially improve the lives of patients and their loved ones. Investment Highlights NUEDEXTA® (dextromethorphan hydrobromide and quinidine sulfate) Profitable Commercial Franchise Avanir Quick Facts Headquarters: Aliso Viejo, CA Stock Listing: NASDAQ: AVNR Staff: Approximately 300 • Large market with a high unmet medical need; ~2 million patients in the U.S. • First and only FDA and EMA approved therapy for pseudobulbar affect (PBA), a neurologic disorder causing sudden, disruptive outbursts of crying or laughing that causes significant functional and quality-of-life impairment. o Occurs in patients with key neurological conditions including amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), stroke, traumatic brain injury (TBI),and dementia Market Capitalization: $914 million* Share Outstanding: 159.8 million** Cash, cash equivalents & restricted investments: $56.5 million*** 52-week Range: $2.62 - $6.00* Fiscal Year End: September 30 • Robust and growing revenues Executive Leadership Team Keith A. Katkin President & Chief Executive Officer Gregory J. Flesher Senior Vice President & Chief Business Officer Rohan Palekar Senior Vice President & Chief Commercial Officer Joao Siffert, MD Senior Vice President & Chief Medical Officer Elona Kogan, Esq. Vice President, Legal Affairs Joanna L. Moore Vice President & Chief Compliance Officer Christine G. Ocampo, CPA Vice President, Finance Jesus Varela Executive Director, Human Resources Broad Development Pipeline Across Three Assets • • • Pain: Migraine, DPN pain Mood/Behavior: Agitation in Alzheimer’s disease, autism, depression Movement Disorders: Dyskinesia, chorea, spasticity A Leading CNS Biopharma • • • Demonstrated commercial success Investing in deep development pipeline to drive potential near and long-term value Infrastructure to grow Corporate Strategy • Organic Growth o Establish NUEDEXTA as a global brand and explore new indications to build an un-paralleled CNS franchise • Inorganic Growth o Acquire rights to products that can leverage our commercial presence in the neurology, psychiatry and long-term care settings as we did with our recent Merck co-promote and OptiNose (AVP-825 in-license) collaborations. *As of June 30, 2014 ** As of April 30, 2014 *** As of March 31, 2014 Pipeline Contact Details Avanir Pharmaceuticals, Inc 30 Enterprise, Suite 400 Aliso Viejo, CA 92656 www.avanir.com +1 (949) 389-6700 Investors/Media Ian Clements, PhD +1 (949) 389-6737 [email protected] Research Coverage Jefferies & Co. Thomas Wei JMP Securities Jason Butler, PhD About AVP-923 AVP-923 is a combination of two well-characterized compounds, the active CNS ingredient dextromethorphan hydrobromide (an uncompetitive NMDA receptor antagonist and sigma-1 receptor agonist) plus low-dose quinidine sulfate (a CYP2D6 enzyme inhibitor), which serves to increase the bioavailability of dextromethorphan. Several dose strengths of AVP923 are being studied in multiple ongoing clinical trials including agitation in Alzheimer's disease, and levodopa-induced dyskinesia in Parkinson's disease. AVP-923 at the 20/10 mg dose strength is approved by the FDA for the treatment of PBA and marketed under the trade name NUEDEXTA (see important safety information below). AVP-923 is an investigational drug not approved by the FDA for any uses other than PBA. Piper Jaffray & Co. Charles Duncan, PhD Mizuho Securities Mario Corso Summer Street Research Partners Carol Werther About AVP-786 AVP-786, the company’s next-generation NUEDEXTA, is a novel investigational drug product consisting of a combination of deuterium modified dextromethorphan and ultra-low dose quinidine, used as a metabolic inhibitor. Incorporation of deuterium into specific positions of the dextromethorphan molecule strengthens the chemical bonds and reduces susceptibility to enzyme cleavage and first pass metabolism, but without altering its pharmacology. AVP-786 is an investigational drug not approved by the FDA. About AVP-825 AVP-825 is an investigational drug-device combination product consisting of low-dose sumatriptan powder delivered intranasally utilizing a novel breath-powered delivery technology. If approved, AVP-825 would be the first and only fast-acting, dry-powder intranasal form of sumatriptan for the treatment of migraine. The Prescription Drug User Fee Act (PDUFA) V goal date is November 26, 2014. AVP-825 is an investigational drug not approved by the FDA. This fact sheet is a summary of more detailed disclosure that can be found in Avanir’s filings with the U.S. Securities and Exchange Commission and its press releases. This fact sheet contains forward-looking statements that involve significant risks and uncertainties, discussion of which can be found in Avanir’s most recent Forms 10-K, 10-Q, and 8-K. The information in this fact sheet is given as of the date below, and Avanir does not undertake any obligation to update any information in this document. Revision Date: June 30, 2014 Important Safety Information NUEDEXTA (dextromethorphan hydrobromide and quinidine sulfate) is the first and only FDA-approved treatment for pseudobulbar affect (PBA). NUEDEXTA (dextromethorphan hydrobromide and quinidine sulfate) 20/10 mg capsules can interact with other medications and cause serious side effects. NUEDEXTA is contraindicated in patients taking certain drugs and in patients with specific cardiovascular risk factors. These are not all the risks from use of NUEDEXTA. For additional Important Safety Information and the full Prescribing Information, please visit www.NUEDEXTA.com © 2014 Avanir Pharmaceuticals, Inc